159 related articles for article (PubMed ID: 11205469)
1. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up.
Ibrahim NK; Buzdar AU; Asmar L; Theriault RL; Hortobagyi GN
Ann Oncol; 2000 Dec; 11(12):1597-601. PubMed ID: 11205469
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Ibrahim NK; Frye DK; Buzdar AU; Walters RS; Hortobagyi GN
Arch Intern Med; 1996 Apr; 156(8):882-8. PubMed ID: 8774207
[TBL] [Abstract][Full Text] [Related]
3. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
Lluch A; Ojeda B; Colomer R; Barnadas A; Massuti B; Casado A; Angeles C; Maroto P
Cancer; 2000 Dec; 89(11):2169-75. PubMed ID: 11147586
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
6. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
7. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
9. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
10. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
11. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
Tahover E; Segal A; Isacson R; Rosengarten O; Grenader T; Gips M; Cherny N; Heching NI; Mesika L; Catane R; Gabizon A
Anticancer Drugs; 2017 Aug; 28(7):787-794. PubMed ID: 28562379
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Rivera E; Holmes FA; Buzdar AU; Asmar L; Kau SW; Fraschini G; Walters R; Theriault RL; Hortobagyi GN
Breast J; 2002; 8(1):2-9. PubMed ID: 11856154
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
15. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
Fowble B; Hanlon AL; Patchefsky A; Freedman G; Hoffman JP; Sigurdson ER; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):105-15. PubMed ID: 9747827
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
[TBL] [Abstract][Full Text] [Related]
18. Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients.
Mora EM; Singletary SE; Buzdar AU; Johnston DA
Ann Surg Oncol; 1996 Mar; 3(2):162-8. PubMed ID: 8646517
[TBL] [Abstract][Full Text] [Related]
19. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"?
Oh JL; Bonnen M; Outlaw ED; Schechter NR; Perkins GH; Strom EA; Babiera G; Oswald MJ; Allen PK; Thames HD; Buchholz TA
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1345-52. PubMed ID: 16750315
[TBL] [Abstract][Full Text] [Related]
20. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]